The clinical successes in cancer immunotherapy have led to a critical need for biomarkers in cancer immunotherapy. It is of the utmost importance to know who is most likely to benefit from these therapies (predictive biomarkers) but also who is starting to respond (prognostic biomarkers) and how the therapy functions in order to make rational combination choices (mechanism of action biomarkers). The Society for Immunotherapy of Cancer (SITC) Biomarkers Task Force addressed the state of the art and made a series of recommendations for the field, which is summarized here.

中文翻译：

---

癌症生物标志物免疫疗法学会特别工作组建议复查

癌症免疫疗法的临床成功导致了对癌症免疫疗法中生物标志物的迫切需求。最重要的是要知道谁最有可能从这些疗法中受益（预测性生物标志物），同时又是谁开始做出反应（预后性生物标志物）以及该疗法如何发挥作用以做出合理的组合选择（作用生物标志物机制） 。癌症免疫疗法协会（SITC）生物标志物工作组着手介绍了最新技术，并针对该领域提出了一系列建议，在此进行了总结。